NCT02032823
Disease Type: Breast
Status: Open
Trial Information
A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Click here for more information
This trial is available at:
Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499
Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463
Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145
For more information, please contact: